Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | MET | P08581 | 2/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 14/20 | 0.61 |
| ▸ | INSR | P06213 | 12/20 | 0.61 |
| ▸ | IGF1R | P08069 | 12/20 | 0.61 |
| ▸ | PLK1 | P53350 | 3/20 | 0.60 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | STK25 | O00506 | 1/20 | 0.54 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | CASK | O14936 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.54 |
| ▸ | MUSK | O15146 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22518897 | 0.91 | EGFR (0.82) | EGFRMETALKINSRIGF1R | |
| SCHEMBL22518892 | 0.91 | EGFR (0.83) | EGFRMETALKINSRIGF1R | |
| SCHEMBL24074211 | 0.85 | EGFR (0.63) | EGFRMETALKINSRIGF1R | |
| SCHEMBL29045195 | 0.82 | INSR (0.71) | EGFRMETALKINSRIGF1R | |
| SCHEMBL22518904 | 0.82 | EGFR (0.87) | EGFRMETALKINSRIGF1R | |
| SCHEMBL21432183 | 0.82 | EGFR (1.00) | EGFRMETALKINSRIGF1R | |
| SCHEMBL22518888 | 0.81 | EGFR (0.82) | EGFRMETALKINSRIGF1R | |
| SCHEMBL24327332 | 0.80 | ALK (0.67) | EGFRMETALKINSRIGF1R | |
| SCHEMBL21432250 | 0.79 | EGFR (0.94) | EGFRMETALKINSRIGF1R | |
| SCHEMBL23378028 | 0.79 | EGFR (0.81) | EGFRMETALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024242360-A1 | CANCER THERAPEUTIC AGENT MEDIATED BY ALK | 주식회사 온코빅스 | 2024-11-28 | — | — | WO | claimed |
| EP-3722292-B1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| CN-111386266-B | Pyrimidine derivatives having cancer cell growth inhibiting effect and pharmaceutical compositions containing the same | 昂科比克斯有限公司 | 2023-08-04 | — | — | CN | claimed |
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2022-02-15 | — | — | US | claimed |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2021-05-20 | — | — | US | claimed |
| EP-3722292-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2020-10-14 | — | — | EP | claimed |
| CN-111386266-A | Novel pyrimidine derivative having cancer cell growth inhibitory effect and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2020-07-07 | — | — | CN | claimed |
| WO-2024242360-A1 | CANCER THERAPEUTIC AGENT MEDIATED BY ALK | 주식회사 온코빅스 | 2024-11-28 | — | — | WO | disclosed |
| EP-3722292-B1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-111386266-B | Pyrimidine derivatives having cancer cell growth inhibiting effect and pharmaceutical compositions containing the same | 昂科比克斯有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | ONCOBIX CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO., LTD. (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-3722292-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2020-10-14 | — | — | EP | disclosed |
| CN-111386266-A | Novel pyrimidine derivative having cancer cell growth inhibitory effect and pharmaceutical composition comprising same | 昂科比克斯有限公司 | 2020-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248003-B2 | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | MET, EGFR, TYMS | EGFR 2/4885MET 1/4885ALK 94/4885 |
| US-20210147439-A1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | MET, EGFR, TYMS | EGFR 2/4885MET 1/4885ALK 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.